ARS Pharmaceuticals, Inc. (SPRY) Total liabilities 2021–2025
ARS Pharmaceuticals, Inc. (SPRY) total liabilities at each fiscal year-end, per SEC filings.
$213.4MFY2025 · since FY2021: $16.7M → $213.4M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $213.4M | +126.2% |
| FY2024 | $94.4M | +3786.1% |
| FY2023 | $2.4M | -71.6% |
| FY2022 | $8.5M | -48.7% |
| FY2021 | $16.7M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice